SEARCH

SEARCH BY CITATION

References

  • 1
    Ferlay J, Shin H-R, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893917.
  • 2
    Cancer Research UK. Cervical Cancer – UK Incidence statistics. 2012. [http://infocancerresearchukorg/cancerstats/types/cervix/incidence/] Accessed 16 January 2012.
  • 3
    Facey K, Bradbury I, Laking G, Payne E. Overview of the clinical effectiveness of positron emission tomography imaging in selected cancers. Health Technol Assess, 2007. 11.
  • 4
    Anon. Topotecan (Hycamtin®) for the treatment of recurrent and stage IVB carcinoma of the cervix. Single Technology Appraisal (STA) submission to the National Institute for Health and Clinical Excellence. London: GlaxoSmithKline; 2009.
  • 5
    Meads C, Auguste P, Davenport C, Małysiak S, Sundar S, Kowalska M, et al. Effectiveness of PET-CT imaging in detecting and managing re-current cervical cancer: systematic review of evidence and economic modelling. Health Technol Assess, 2013;17.
  • 6
    Meads C, Davenport C, Małysiak S, Kowalska M, Zapalska A, Chomiak P, et al. Evaluating PET-CT in the detection and management of recurrent cervical cancer: systematic reviews of diagnostic accuracy and subjective elicitation. Health Technol Assess, 2013;17.
  • 7
    National Institute for Health and Clinical Excellence (NICE). Guide to the methods of technology appraisal. NICE, 2008. [www.nice.org.uk/media/b52/a7/tamethodsguideupdatedjune2008.pdf] Accessed 16 January 2013.
  • 8
    Sonnenberg FA, Beck JR. Markov models in medical decision making. Med Decis Making 1993;13:32238.
  • 9
    Landoni F, Maneo A, Colombo A, Placa F, Milani R, Perego P, et al. Randomised study of radical surgery versus radiotherapy for stage Ib-IIa cervical cancer. Lancet 1997;350:53540.
  • 10
    Keys HM, Bundy BN, Stehman FB, Muderspach LI, Chafe WE, Suggs CL, et al. Cisplatin, radiation, and adjuvant hysterectomy compared with radiation and adjuvant hysterectomy for bulky stage IB cervical carcinoma. N Engl J Med 1999;340:115461.
  • 11
    Vale CL, Tierny JF, Davidson SE, Drinkwater KJ, Symonds P. Substantial improvement in uk cervical cancer survival with chemoradiotherapy: results of a Royal College of Radiologists' audit. Clin Oncol 2010;22:590601.
  • 12
    Jain P, Hunter RD, Livsey JE, Coyle C, Swindell R, Davidson SE. Salvaging locoregional recurrence with radiotherapy after surgery in early cervical cancer. Clin Oncol 2007;19:7638.
  • 13
    Pearcey R, Brundage M, Drouin P, Jeffrey J, Johnston D, Lukka H, et al. Phase III trial comparing radical radiotherapy with and without cisplatin chemotherapy in patients with advanced squamous cell cancer of the cervix. J Clin Oncol 2002;20:96672.
  • 14
    Maneo A, Landoni F, Cormio G, Colombo A, Placa F, Pellegrino A, et al. Concurrent carboplatin/5-fluorouracil and radiotherapy for recurrent cervical carcinoma. Ann Oncol 1999;10:8037.
  • 15
    Beitler JJ, Anderson PS, Wadler S, Runowicz CD, Hayes MK, Fields AL, et al. Pelvic exenteration for cervix cancer: would additional intraoperative interstitial brachytherapy improve survival? Int J Radiat Oncol Biol Phys 1997;38:1438.
  • 16
    DH - PbR - Finance and Costing team. Reference Costs 2009–10 Publicationpbrdatacollection. London: Department of Health; 2011.
  • 17
    Brush J, Boyd K, Chappell F, Crawford F, Dozier M, Fenwick E, et al. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation. 2011. pp. 1192.
  • 18
    Clark J, Barton P, Gupta J, Khan K. Outpatient diagnosis of endometrial cancer in women with first episode of postmenopausal bleeding. Birmingham: West Midlands Health Technology Assessment Collaboration, Department of Public Health and Epidemiology, University of Birmingham; 2002. Report No.: 51.
  • 19
    Curtis L. Unit costs of health and social care. Canterbury: Personal Social Services Research Unit, University of Kent; 2010.
  • 20
    Goldie SJ, Kohli M, Grima D, Weinstein M, Wright TC, Bosch FX, et al. Projected clinical benefits and cost-effectiveness of a human papillomavirus 16/18 vaccine. J Natl Cancer Inst 2004;96:60415.
  • 21
    Salani R, Backes FJ, Fung Kee Fung M, Holschneider CH, Parker LP, Bairstow RE, et al. Posttreatment surveillance and diagnosis of recurrence in women with gynecologic malignancies: Society of Gynecologic Oncologists recommendations. Am J Obstet Gynecol 2011;204:46678.
  • 22
    Adriano E, Jagoe JM, Harrison T, Riffenburgh RH, Johnstone PAS. Survival of patients with untreated cervical carcinoma. Am J Clin Oncol 2003;26:36973.
  • 23
    Lang H-C, Chang K, Ying Y-H. Quality of life, treatments, and patients' willingness to pay for a complete remission of cervical cancer in Taiwan. Health Econ 2012;21:121733.